Literature DB >> 20304332

Seizure susceptibility due to antihistamines in febrile seizures.

Tomoyuki Takano1, Yuko Sakaue, Tatsuyuki Sokoda, Chihiro Sawai, Shie Akabori, Yoshihiro Maruo, Takashi Taga, Masaki Ohno, Yoshihiro Takeuchi.   

Abstract

The aim of this study was to determine whether seizure susceptibility due to antihistamines is provoked in patients with febrile seizures. The study population comprised 14 patients with simple febrile seizures and 35 patients with complex febrile seizures. Detailed clinical manifestations were compared between patients with and without administration of antihistamine. The time from fever detection to the seizure onset was significantly shorter in the antihistamine group than that in the nonantihistamine group, and the duration of seizures was significantly longer in the antihistamine group than that in nonantihistamine group. Interleukin-1beta is thought to be associated with causing febrile seizures via its dual role as a pyrogen and convulsant substance. Moreover, interleukin-1beta may activate the turnover of hypothalamic neural histamine. These considerations, along with the present results, suggest that the depletion of hypothalamic neuronal histamine induced by antihistamines may increase neuronal excitability, thereby increasing seizure susceptibility in patients with febrile seizures. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20304332     DOI: 10.1016/j.pediatrneurol.2009.11.001

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  10 in total

Review 1.  Histamine receptor signaling in energy homeostasis.

Authors:  Iustin V Tabarean
Journal:  Neuropharmacology       Date:  2015-06-21       Impact factor: 5.250

Review 2.  Histamine H3 receptor antagonists in relation to epilepsy and neurodegeneration: a systemic consideration of recent progress and perspectives.

Authors:  M Bhowmik; R Khanam; D Vohora
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 3.  Efficacy and Safety of Non-brain Penetrating H1-Antihistamines for the Treatment of Allergic Diseases.

Authors:  Kazuhiko Yanai; Takeo Yoshikawa; Martin K Church
Journal:  Curr Top Behav Neurosci       Date:  2022

4.  Histamine H1 antagonists and clinical characteristics of febrile seizures.

Authors:  Mohammed A Zolaly
Journal:  Int J Gen Med       Date:  2012-03-20

Review 5.  Febrile seizures.

Authors:  Sajun Chung
Journal:  Korean J Pediatr       Date:  2014-09-30

Review 6.  Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target Drugs.

Authors:  Dubravka Svob Strac; Nela Pivac; Ilse J Smolders; Wieslawa A Fogel; Philippe De Deurwaerdere; Giuseppe Di Giovanni
Journal:  Front Neurosci       Date:  2016-11-10       Impact factor: 4.677

7.  Anticonvulsant effects of isomeric nonimidazole histamine H3 receptor antagonists.

Authors:  Bassem Sadek; Ali Saad; Johannes Stephan Schwed; Lilia Weizel; Miriam Walter; Holger Stark
Journal:  Drug Des Devel Ther       Date:  2016-11-07       Impact factor: 4.162

8.  The Neuroprotective Effects of Histamine H3 Receptor Antagonist E177 on Pilocarpine-Induced Status Epilepticus in Rats.

Authors:  Alaa Alachkar; Sheikh Azimullah; Shreesh K Ojha; Rami Beiram; Dorota Łażewska; Katarzyna Kieć-Kononowicz; Bassem Sadek
Journal:  Molecules       Date:  2019-11-14       Impact factor: 4.411

Review 9.  Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?

Authors:  Changbo Qu; Gwenny M Fuhler; Yihang Pan
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

10.  Non-imidazole-based histamine H3 receptor antagonists with anticonvulsant activity in different seizure models in male adult rats.

Authors:  Bassem Sadek; Ali Saad; Gniewomir Latacz; Kamil Kuder; Agnieszka Olejarz; Tadeusz Karcz; Holger Stark; Katarzyna Kieć-Kononowicz
Journal:  Drug Des Devel Ther       Date:  2016-11-25       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.